Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 ANI Acquires Branded Products Portfolio from Sandoz | Contract Pharma

What are you searching for?

Sign in
Breaking News

ANI Acquires Branded Products Portfolio from Sandoz

Enter multi-year manufacturing and supply agreement.

Author Image

By: Charlie Sternberg

Associate Editor, Contract Pharma

ANI Pharmaceuticals Inc. has acquired the new drug applications (NDAs) for Oxistat Lotion, Veregen Ointment, and Pandel Cream and the abbreviated new drug application (ANDA) for ApexiCon E Cream from Sandoz Inc. Pandel Cream will be transitioned later upon receiving the requisite approvals.
 
Collectively, these products generated net revenues of $13.2 million in 2020. The acquisition was funded through borrowings under the Company’s pre-existing revolver credit facility.
 
In conjunction with the acquisition, ANI and Sandoz have entered into a multi-year manufacturing and supply agreement for Oxistat Lotion, Pandel Cream and ApexiCon E Cream. ANI intends to transfer the manufacture and packaging of these three products to its own manufacturing sites in the future.
 
“This acquisition is in line with our strategy to expand our established brands business through accretive deals. Importantly, ANI will ensure that patients in need continue to receive these high-quality dermatology products. The acquisition leverages our innovative brand commercialization infrastructure and our North American manufacturing footprint,” stated Nikhil Lalwani, president and CEO.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters